IL6 and hepatocellular carcinoma: Blocking either CAF IL-6 or myeloid STAT3 can disrupt signaling from CAFs to myeloid cells and attenuate immunosuppression in hepatocellular carcinoma (HCC) and pancreatic cancer (Deng et al., 2017; Chomarat et al., 2000; Mace et al., 2013).